Lilly’s Q2 Beat Widens Leadership Gap as Market Punishes Novo’s Uncertainty

What happened

Both Eli Lilly and Novo Nordisk surpassed second-quarter estimates and raised full-year guidance, but the market’s reaction was starkly different—Lilly shares surged while Novo was punished, highlighting a growing divide in investor confidence. Lilly’s Q2 revenue jumped 48% to $22.97 billion, driven by massive Mounjaro and Zepbound sales, while price erosion remained manageable at 13% consolidated. Novo’s results, though strong, failed to dispel concerns over its oral ramp and pricing pressure, reinforcing Wall Street’s view that Lilly’s deeper pipeline and execution are pulling ahead. Despite the beat, the DeepValue report cautions that the stock already trades at 39.6x earnings with no margin of safety, leaving the thesis dependent on volume growth consistently outpacing rebates and on Foundayo’s ambiguous uptake converting into clear revenue. The next two quarterly filings must demonstrate that Medicare Bridge and PBM access improve volume without worsening net pricing, or the premium valuation will come under pressure.

Implication

The market is now pricing Lilly as the undisputed GLP-1 leader, so any misstep—whether in pricing, oral uptake, or retatrutide’s timeline—will trigger sharp revaluation. Investors should closely monitor whether the next 10-Q shows volume still handily outrunning rebates, as the 13% price drag must stay stable or narrow. Foundayo’s commercial acceleration after expanded PBM and Medicare access is critical; until management moves beyond ‘unknown uptake’ language, the oral thesis remains speculative. Retatrutide must file by Q1 2027 with no slippage, or the next-generation growth narrative will fracture. Given the current price, risk-reward is skewed: waiting for a pullback toward the $980–$1,000 range or for harder evidence of durable, high-quality growth offers better entry.

Thesis delta

The thesis remains unchanged—WAIT with an attractive entry below $980—but the Q2 beat and market reaction underscore Lilly’s competitive moat and raise the bar for future execution. The stock’s move deeper into overvalued territory amplifies the need for concrete proof that volume will keep overpowering price erosion and that oral and triple-agonist assets will convert access into visible revenue; without that, the current premium is unsustainable.